Nutra Pharma Corp. (NPHC) Stock

About Nutra Pharma Corp.

Nutra Pharma Corp. (NPHC) operates as a biopharmaceutical firm specializing in obtaining, licensing, and bringing to market a variety of pharmaceutical products, cutting-edge technologies, and both homeopathic and ethical medications. The company primarily targets the U.S. market, focusing its efforts on managing conditions such as pain, neurological ailments, cancer, autoimmune diseases, and infectious diseases. Its current commercial offerings include: Nyloxin and Nyloxin Extra Strength: These products are distributed as an oral spray for alleviating lower back pain, migraines, neck and shoulder discomfort, cramps, and neuropathic pain, and as a topical gel to relieve joint pain, arthritis, and repetitive stress injuries. Pet Pain-Away: An over-the-counter (OTC) homeopathic, non-narcotic, and non-addictive solution for chronic pain in household pets. Luxury Feet: An OTC pain reliever and anti-inflammatory designed to ease foot pain or discomfort specifically caused by high heels and stilettos. Nyloxin Military Strength: A specialized formulation for pain relief aimed at the United States Military and Veteran's Administration. Equine Pain-Away: An OTC topical pain management product for horses. Beyond its existing portfolio, Nutra Pharma Corp. is also advancing several pipeline candidates: RPI-78M: In development to treat neurological conditions such as multiple sclerosis, adrenomyeloneuropathy, and amyotrophic lateral sclerosis, alongside autoimmune diseases like rheumatoid arthritis and myasthenia gravis. RPI-MN: Under investigation for viral diseases, including human immunodeficiency virus (HIV/AIDS) and herpes, as well as for general antiviral applications. RPI-78: Being developed for applications in pain and arthritis. RPI-70: Also in development for pain relief. Founded in 2000, the company is headquartered in Plantation, Florida.

Nutra Pharma Corp. (NPHC) stock trades at $0.00 with a market capitalization of $2.15M. The stock is valued at a price-to-earnings (P/E) ratio of -1.00, price-to-book of -0.14, price-to-sales of 8.36. Over the past 52 weeks the stock has ranged between $0.00 and $0.01, and currently trades 100.0% below its 52-week high.

On profitability, Nutra Pharma Corp. generates a return on equity (ROE) of 11.76%, return on capital employed of 8.71%, an operating margin of -580.33%, a net profit margin of -428.76%.

Official website: www.nutrapharma.com